our mission

TriSalus Life Sciences® seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and our investigational immunotherapy.

Illustration of the two organs, two problems, two solutions approach that TriSalus is working on. Two organs: the liver and pancreas in an elderly, male patient. Addressing two problems: immunosuppression and tumor pressure which causes blood vessel collapse. Combining two solutions: immunotherapy via pressure enabled drug delivery.
Addressing two problems: immunosuppression and tumor pressure which causes blood vessel collapse.
Combining two solutions: immunotherapy via pressure enabled drug delivery.

We’re developing a transformative platform to address barriers to the treatment of liver and pancreatic tumors.

Two critical barriers, intratumoral pressure and an immunosuppressive environment, limit the delivery and efficacy of immunotherapies in tumors of the liver and pancreas.

We believe that comprehensively addressing these two barriers has the potential to improve the lives of patients with liver and pancreatic tumors. Our therapeutic platform is designed to be used in combination with, and enable, systemic immunotherapies like checkpoint inhibitors.

Our Science

Learn about how TriSalus aims to address two of the most significant barriers to treatment.

 

Video Thumbnail with text: Prologue
Play Video about Video Title Slide: Prologue
See Our Platform in Action

TriSalus takes an integrated approach tailored to the target organ and disease biology, with the goal to overcome two critical barriers: immunosuppression and delivery.

Watch to learn how our platform approach applies to the treatment of liver tumors.

Share video

Recent News

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

March 27, 2025

TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

March 26, 2025

TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”

March 06, 2025

Our Pipeline

We’re studying the integration of the Pressure-Enabled Drug Delivery™ (PEDD™) method with therapies capable of reactivating immune cells to enable immunotherapies in the liver and pancreas. Our clinical research is focused on bringing this potentially transformative treatment platform to patients.

PIPELINE

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

CANCEL